Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shared Savings Legislation Could Increase Medicare Biosimilar Access

Proposed Three-Year Project Would Assess Benefit Of Additional Payments

Executive Summary

Congressman Richard Hudson has introduced US legislation calling for a three-year ‘demonstration project’ into a shared savings payment scheme for biosimilar medicines provided through Medicare Part B.

You may also be interested in...

AAM Sees Boon From Biden Order And CMS Biosimilar Action

The US Association for Accessible Medicines has welcomed an executive order from president Joe Biden aimed at lowering prescription drug costs, shortly after the AAM’s Biosimilars Council praised payment changes for biosimilars made by the Centers for Medicare & Medicaid Services.

Medicare Part B Payment Boost For Biosimilars A Positive Step But ‘More Must Be Done’

The policy is welcomed by biosimilar stakeholders, but amounts to a relatively small increase. To qualify for the revised payment, a biosimilar must have an average sales price that is less than its reference drug’s ASP and not all do.

Biosimilar Use, Cost Trends In Medicare Part B Will Be Examined By HHS Inspector General

If study finds biosimilar uptake in the Part B program is lagging, it may inform policy changes to encourage gains. On the other hand,  the latest biosimilars trend reports from Cardinal Health and Amgen show follow-ons are controlling share in some markets for physician-administered drugs and savings are adding up.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts